Timothy C. Barabe, Director at Cartesian Therapeutics, Inc. (RNAC), bought 7,500 shares at $12.70 ($95K) on 2024-08-12, disclosed to the SEC on 2024-08-14.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |
| SELB | BUY | 2021-08-20 | $36K | — | Filing → |
| SELB | BUY | 2021-03-30 | $41K | — | Filing → |
| VEEV | SELL | 2020-10-15 | $798K | — | Filing → |